CD4 and mitochondrial DNA depletion syndrome 4a: In support of this, all the rapid diagnostic tests have been reported to be cost-effective, clinically useful and can be accessible through the Pan American Health Organization (PAHO) Strategic Fund.32, 33, 34, 35 AHD remains a significant challenge, particularly in resource-limited settings where access to diagnostic tools such as CD4 testing is often restricted.